Hematologic and Cytogenetic Responses in Imatinib-Resistant Chronic Phase Chronic Myeloid Leukemia Patients Treated with the Dual SRC/ABL Kinase Inhibitor BMS-354825: Results from a Phase I Dose Escalation Study.
暂无分享,去创建一个
C. Sawyers | H. Kantarjian | A. DeCillis | F. Huang | N. Donato | M. Talpaz | N. Shah | J. Nicoll | S. Bai | E. Clark